August 25, 2015
An Indiana federal judge on Tuesday ruled that Teva Parenteral Medicines Inc.'s proposed labeling for a generic version of the cancer drug Alimta would cause physicians to infringe Eli Lilly & Co.'s vitamin-regimen patent.
July 23, 2015
Eli Lilly and Co. on Wednesday criticized as "startling" Teva Parenteral Medicines Inc.'s post-trial brief in a fight over whether Teva's labeling on a generic version of the cancer drug Alimta causes physicians to infringe Lilly's patent, saying Teva is asking the court to ignore the evidence from a May bench trial.
March 31, 2014
An Indiana federal judge on Monday upheld the validity of Eli Lilly & Co.'s patent for administering its blockbuster cancer treatment drug Alimta, finding that Teva Parenteral Medicines Inc.'s application for a generic version of the drug infringes the patent.